Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
AL008 is a novel, investigational, antibody product candidate targeting the CD47-SIRP-alpha (SIRPα) pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. AL008 is a potential best-in-class SIRPα inhibitor with a unique dual mechanism of action that non‑competitively antagonizes the CD47- SIRPα pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (a “don’t eat me signal”) while also engaging and activating Fcγ gamma receptor (FcγgammaR) to promote immuno-stimulatory pathways that drive anti-tumor immunity.
The virtual scientific meetings include the:
- Macrophage-Directed Therapies Summit
Date and Time:Wednesday, October 28, 2020 at10:30 a.m. EST
Presentation: A Novel Approach to Targeting the SIRPα Checkpoint Pathway and FcγgammaR Signaling
Presenter:Spencer Liang , Ph.D., senior director and head of immuno-oncology
- CD47|SIRPα Summit
Date and Time:Wednesday, November 4, 2020 at4:30 p.m. EST
Panel: What are the Predictive Biomarkers Arising When Targeting CD47|SIRPα Pathways?
Presenter:Spencer Liang , Ph.D., senior director and head of immuno-oncology
Date and Time:Thursday, November 5, 2020 at11:35 a.m. EST
Presentation: An Insight into Alector’s Novel Approach to Drive Anti-Tumor Immunity Targeting CD47|SIRPα Pathways
Presenter: Andrew Picentic, Ph.D., senior staff scientist and group leader
Date and Time:Thursday, November 5, 2020 at11:35 a.m. EST
Panel: How Can We Manage Toxicity and Improve Clinical Practice in Targeting CD47|SIRPα Pathways?
Presenter:Daniel Maslyar , M.D., vice president of clinical development, oncology
“We are pleased to be highlighting the progress of our early-stage immuno-oncology programs at two notable research forums,” said
About Alector
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco,
Contacts
Media:
Vice President, Communications and Public Affairs
301-928-4650
erica.jefferson@alector.com
1AB
973-271-6085
dan@1abmedia.com
or
Investors:
ir@alector.com
Source: Alector, Inc.